Pharmaceutical researchers have released new data showing that a next-generation obesity treatment known as CagriSema delivered an average body weight reduction of up to 25% among women participating in late-stage clinical research.
The results highlight the continuing evolution of obesity medicine beyond first-generation GLP-1 therapies. Researchers believe future treatments could offer improved long-term weight management, better metabolic health outcomes, and additional options for patients who struggle with current therapies.
About the Author
